Philadelphia, United States
NodThera, founded in 2016, is carving a niche within the Biotechnology, Health Care, and Life Sciences sectors. The company's groundbreaking work focuses on developing a novel class of potent and highly selective NLRP3 inflammasome inhibitors, potentially revolutionizing the treatment of chronic inflammation-driven diseases.
Operating from offices in Cambridge, UK and Boston, MA, NodThera prides itself on a diverse and dynamic team driven by shared ambition and innovation. The slogan "Treating chronic disease by targeting inflammation at its source" encapsulates their mission.
The company received a significant financial boost with a $55.00M Series B investment on 03 June 2020. This round was backed by noteworthy investors including F-Prime Capital, Sofinnova Partners, 5AM Ventures, Cowen Digital, Epidarex Capital, Sanofi Ventures, and Novo Ventures, indicating strong confidence in NodThera's innovative potential and future trajectory.
